Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

PET a tool for assessing the in vivo tumour cell and its microenvironment?

Buscombe JR, Wong B.

Br Med Bull. 2013;105:157-67. doi: 10.1093/bmb/lds041. Epub 2013 Jan 29. Review.

PMID:
23360594
2.

Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.

Menichetti L, Cionini L, Sauerwein WA, Altieri S, Solin O, Minn H, Salvadori PA.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S351-4. doi: 10.1016/j.apradiso.2009.03.062. Epub 2009 Apr 2.

PMID:
19410471
3.

Biological imaging in radiation therapy: role of positron emission tomography.

Nestle U, Weber W, Hentschel M, Grosu AL.

Phys Med Biol. 2009 Jan 7;54(1):R1-25. doi: 10.1088/0031-9155/54/1/R01. Epub 2008 Dec 5. Review.

PMID:
19060363
4.

Positron emission tomography for radiation treatment planning.

Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M.

Strahlenther Onkol. 2005 Aug;181(8):483-99. Review.

PMID:
16044216
5.

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):364-72. doi: 10.1007/s00259-012-2286-6. Epub 2012 Nov 14.

PMID:
23151915
6.

Imaging tumour hypoxia with positron emission tomography.

Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ.

Br J Cancer. 2015 Jan 20;112(2):238-50. doi: 10.1038/bjc.2014.610. Epub 2014 Dec 16. Review.

7.

PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.

Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, Theil J, Kallehauge JF, D'Andrea FP, Steiniche T, Horsman MR.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):186-97. doi: 10.1007/s00259-012-2258-x. Epub 2012 Oct 18.

PMID:
23076620
8.

New PET imaging agents in the management of solid cancers.

Garcia C, Gebhart G, Flamen P.

Curr Opin Oncol. 2012 Nov;24(6):748-55. doi: 10.1097/CCO.0b013e32835766f7. Review.

PMID:
22913970
9.

Methodological aspects on hypoxia PET acquisition and image processing.

Thorwarth D, Mönnich D, Zips D.

Q J Nucl Med Mol Imaging. 2013 Sep;57(3):235-43. Review.

PMID:
24045620
10.

Imaging hypoxia in tumours with advanced MRI.

Price JM, Robinson SP, Koh DM.

Q J Nucl Med Mol Imaging. 2013 Sep;57(3):257-70. Review.

11.

Gallium-68 PET: a new frontier in receptor cancer imaging.

Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D.

Anticancer Res. 2007 Nov-Dec;27(6B):4087-94. Review.

12.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.

J Nucl Med. 2009 Sep;50(9):1427-34. doi: 10.2967/jnumed.108.053421. Epub 2009 Aug 18.

13.

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.

Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A.

J Nucl Med. 2012 Aug;53(8):1207-15. doi: 10.2967/jnumed.111.101469. Epub 2012 Jul 10.

14.

Monitoring response to therapeutic interventions in patients with cancer.

Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M.

Semin Nucl Med. 2009 May;39(3):210-32. doi: 10.1053/j.semnuclmed.2008.12.001. Review.

PMID:
19341841
15.

Quantifying tumour hypoxia by PET imaging--a theoretical analysis.

Toma-Daşu I, Daşu A, Brahme A.

Adv Exp Med Biol. 2009;645:267-72.

PMID:
19227481
16.

Current concepts on imaging in radiotherapy.

Lecchi M, Fossati P, Elisei F, Orecchia R, Lucignani G.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):821-37. Epub 2007 Oct 31.

PMID:
17972074
17.

Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography.

Wijsman R, Kaanders JH, Oyen WJ, Bussink J.

Q J Nucl Med Mol Imaging. 2013 Sep;57(3):244-56. Review.

18.

Positron emission tomography in oncology.

Berry JD, Cook GJ.

Br Med Bull. 2006;79-80:171-86. Epub 2006 Dec 14. Review.

PMID:
17169969
19.
20.

Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.

Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Döbert N, Hamscho N, Grünwald F.

Acta Med Austriaca. 2003;30(2):37-40.

PMID:
12752086

Supplemental Content

Support Center